- Home
- TLSA vs IMUX Comparison
TLSA vs IMUX Comparison
Compare TLSA & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- IMUX
- Stock Information
- Founded
- TLSA 2013
- IMUX 2016
- Country
- TLSA United Kingdom
- IMUX United States
- Employees
- TLSA N/A
- IMUX N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- IMUX Health Care
- Exchange
- TLSA Nasdaq
- IMUX Nasdaq
- Market Cap
- TLSA 87.8M
- IMUX 86.3M
- IPO Year
- TLSA 2000
- IMUX N/A
- Fundamental
- Price
- TLSA $0.79
- IMUX $1.00
- Analyst Decision
- TLSA
- IMUX Strong Buy
- Analyst Count
- TLSA 0
- IMUX 6
- Target Price
- TLSA N/A
- IMUX $12.67
- AVG Volume (30 Days)
- TLSA 1.1M
- IMUX 923.9K
- Earning Date
- TLSA 02-25-2025
- IMUX 02-24-2025
- Dividend Yield
- TLSA N/A
- IMUX N/A
- EPS Growth
- TLSA N/A
- IMUX N/A
- EPS
- TLSA N/A
- IMUX N/A
- Revenue
- TLSA N/A
- IMUX N/A
- Revenue This Year
- TLSA N/A
- IMUX N/A
- Revenue Next Year
- TLSA N/A
- IMUX N/A
- P/E Ratio
- TLSA N/A
- IMUX N/A
- Revenue Growth
- TLSA N/A
- IMUX N/A
- 52 Week Low
- TLSA $0.41
- IMUX $0.92
- 52 Week High
- TLSA $1.74
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- TLSA 56.56
- IMUX 50.39
- Support Level
- TLSA $0.65
- IMUX $0.92
- Resistance Level
- TLSA $0.70
- IMUX $0.97
- Average True Range (ATR)
- TLSA 0.05
- IMUX 0.06
- MACD
- TLSA 0.01
- IMUX 0.01
- Stochastic Oscillator
- TLSA 100.00
- IMUX 66.61
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.